Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease - Wikidata - awgldk - TriplyDB

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

http://www.wikidata.org/entity/Q35119389

about

Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2 Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease What does it mean to be 'amyloid-positive'?CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes.Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition.Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.Is amyloid-β harmful to the brain? Insights from human imaging studies Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.Amyloid biomarkers: pushing the limits of early detection.Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.Circulating insulin-like growth factor 1 and insulin-like growth factor binding protein-3 level in Alzheimer's disease: a meta-analysis.A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.Commentary: Sleep Changes without Medial Temporal Lobe or Brain Cortical Changes in Community-Dwelling Individuals with Subjective Cognitive Decline.The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity.Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design.Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

P2860

Q26784569-AB209501-645C-4579-92BE-716F6E04A5BF Q26801654-E0AB6A83-B01D-4707-AA1C-F5A5DB6103DB Q28273817-A436CA4D-62B5-4060-B645-35F0A6FFECF2 Q30981669-CF138BFF-28AB-4B2D-8416-F1EE3A150EC5 Q33604453-4DD06687-9BE8-4A94-B103-4CE9D66CFC7D Q33695122-6F3C4C14-1313-478D-89A9-0093BE1C172E Q34477459-B3C8619D-00F9-44E0-8852-4BAFB21F0F01 Q34493453-230FA222-FF94-420D-BEBF-96DBC1C22CAA Q35533944-7EDB25CB-7AAF-4008-929F-571412E0AFB7 Q36169215-417518A0-18B6-4747-A76E-3391A6154988 Q36276506-A962A712-6053-4B04-B9BD-989737D0B7E0 Q36383749-2D43E9B8-A14D-4F5D-8B3D-58FB8EF47AB2 Q36404504-5949344A-02E3-4CA0-BA01-64EEA5511051 Q36473298-43C1A31B-3280-4A8E-8ED1-3A61F98FCD22 Q36515507-EFE5D147-4DF9-4314-AF2D-C43DE781307E Q36639655-EB3ADA42-4CE8-4C3B-80F1-16261F80488B Q36918859-829E4EF5-D70E-451A-BDEF-F9051AD9DDBD Q37188315-B917D8EA-E425-4A7D-8463-EAB486DB09CB Q37198556-EF0D5491-9B5B-4884-85C4-63CF08EAD6C2 Q37220592-8E8891DC-7243-4EED-B7A3-EB0574E9DA71 Q37358410-DFDA23F8-33C5-4260-8E1A-FBD411553E53 Q37489141-CDC0798B-11A0-4B3F-A93A-BDF8A6942501 Q37603879-7E556D86-7D83-4DE5-8EBA-AB8A4BC89F02 Q37627051-6C815360-10BC-42BB-AAD0-B82C74C945C4 Q38391075-51761602-08F4-422F-9E33-44B1213198A6 Q38653401-BDC12E53-1FE8-4E10-811F-6527B073F29D Q38830945-555FFA0D-61C8-431A-BD17-081F7AF70B3B Q39451611-709321E8-E643-4F97-A61D-B43FDE4459A4 Q39630741-A024A7F0-9E4A-4816-B6FC-23341C508515 Q40101067-F85F1969-D062-43F6-B929-FB25C12FB0A3 Q41600997-ABE4C61B-E78F-413B-9AE3-F90C42B4B27F Q42211999-2716D8DF-691B-4F54-B2DA-19C1951D3C2C Q42363366-0FCD867E-D60E-4AFD-8428-F506B70242D2 Q42630406-4BBCA57B-44CA-4FD3-B9B1-C7B09DBA36A8 Q42643417-F3F94EBA-6F37-4938-88DD-E2D830B35451 Q46045880-F758725A-2739-4E34-9AE5-25D9CE6EF588 Q46664880-24475D89-8EAF-458F-ABFA-AF4CA2C43071 Q47134402-9964F0B4-CA42-471E-A1B9-4806D2F6AFDA Q47200597-74C2C4B7-4AE1-4E47-8A37-4C00B145E2C7 Q47209544-52669A48-27C6-4134-8227-767184DEE978

P2860

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

http://www.wikidata.org/entity/Q35119389

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Independent information from c ...... imaging in Alzheimer's disease

@ast

Independent information from c ...... imaging in Alzheimer's disease

@en

type

label

Independent information from c ...... imaging in Alzheimer's disease

@ast

Independent information from c ...... imaging in Alzheimer's disease

@en

prefLabel

Independent information from c ...... imaging in Alzheimer's disease

@ast

Independent information from c ...... imaging in Alzheimer's disease

@en

P1433

Q35119389-266D07A0-E4E9-4377-BE6C-C0CA6665C017

P1476

Q35119389-01C060DC-7931-467C-BE51-C7C45311B5EE

P2093

Q35119389-27E5AC79-9F03-4406-AA43-610A2099421A

Q35119389-5BCE866F-E6CE-4B3F-A5E4-141FB3082B85

Q35119389-8C42BBFC-9EFC-4988-AD0C-7F3922C325B5

Q35119389-8E97376F-A30B-44AF-855F-969C10278EE4

Q35119389-BB6152FD-E601-4947-8586-C6EF3357A3A9

Q35119389-FFEEF37D-6867-49CD-937B-4232D283FB92

P2860

Q35119389-09227B36-E246-48B4-8AE7-78F196A5C219

Q35119389-0969C6DA-1A49-40E4-BFF3-EAA98EF8B115

Q35119389-122BE12E-1315-4854-AF5C-03F7F81F4D01

Q35119389-157172E1-E485-40CF-9649-692AF84468BF

Q35119389-1AF59460-5EF7-493F-9F8C-C1C882E92C0E

Q35119389-244A982A-EFDD-40B4-A34A-7AA022BA1524

Q35119389-2A5577D4-EC71-4428-8164-B6FBCAD722BF

Q35119389-2E4DA1C8-64AF-4534-9A3F-695448995625

Q35119389-35082A4C-A9C3-4570-BDA6-9B505A55E94C

Q35119389-4236022C-B9C8-44F6-88AC-89E57E703B06

P304

Q35119389-72C601EC-EB17-498A-9FAA-2CA731871AAA

P31

Q35119389-F299E06C-CBC1-4E84-8EB0-0F972C08B37E

P356

Q35119389-A7D7C1B5-EA6C-4B0D-AC36-0487C84A019F

P407

Q35119389-CF20B954-4B8A-4175-B6BD-63A239B040DB

P433

Q35119389-FD6CC2BE-E2A2-41E9-8E7F-7DC8A211ED4D

P478

Q35119389-6463DE9A-D1B2-4A3B-8D90-8BD5A585F7EE

P50

Q35119389-4860B3C7-DF31-4E30-B9AB-987D5B4B5670

Q35119389-7049AA67-64BE-4A4A-8D99-6EC3D29174A5

Q35119389-8B7E2621-E287-4783-88D1-FABF00F39A40

Q35119389-CFB47E4D-0D4C-4551-B602-9ABD325A474C

Q35119389-F9AB6924-0C4A-4C9B-8BB0-0EC109C5CFDF

P577

Q35119389-7A57F010-9CEC-4FD0-A37C-1FF624C31376

P5875

Q35119389-073F64C2-1557-4D97-BDA9-1AE9001B43EB

P698

Q35119389-597FF30B-D30F-40EB-9CF0-526C0D084EC8

P921

Q35119389-225533A3-6516-413B-8822-4747D20020E4

Q35119389-5AAF58C1-1EF8-42E2-A3E3-364D8C8F784B

P932

Q35119389-B9896651-C81E-4DBD-8853-65C27D61E7CA

P356

P1433

P1476

Independent information from c ...... imaging in Alzheimer's disease

@en

P2093

Alzheimer's Disease Neuroimaging Initiative*

http://www.w3.org/2001/XMLSchema#string

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Michael Donohue

http://www.w3.org/2001/XMLSchema#string

Philip S Insel

http://www.w3.org/2001/XMLSchema#string

Susan Landau

http://www.w3.org/2001/XMLSchema#string

William J Jagust

http://www.w3.org/2001/XMLSchema#string

P2860

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

P304

772-783

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWU367

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 3

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P50

Michael W. Weiner

Niklas Mattsson

Henrik Zetterberg

John Q. Trojanowski

P577

2014-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270002044

http://www.w3.org/2001/XMLSchema#string

P698

25541191

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

cerebrospinal fluid

P932

4339769

http://www.w3.org/2001/XMLSchema#string